PRTA

Rating neutralAI Memo

Prothena

As of 2026-10-22/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

TargetTau-1 Phase 2 primary completion • 2027-06-30

Base target: $9 / p=50% prob

Biggest risk

The principal trials are partner-controlled, major Phase 3 completions are not expected until 2029, and research collaborations have uncertain timing and economics. The chief development officer resigned effective October 9 to join a strategic partner and lead a partnered program; the filing does not identify that program or establish an operating impact. [#SEC-8K-2026-08-06] [#8-K-2026-10-02]

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Q2 cash and restricted cash was $289.1 million, and the partnered pipeline offers contingent clinical milestones and royalties. A favorable PRX019 decision could bring a $55 million milestone. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-22

Base target

p=50%

Bull target

$13

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Bristol Myers Squibb decision on PRX019
Partnered Phase 3 trial execution
Q2 cash and restricted cash was $289.1 million, and the partnered pipeline offers contingent clinical milestones and royalties.

BearKey bullets

Clinical failure, delay, or a decision not to advance partner-controlled programs could eliminate anticipated milestones.
[#SEC-8K-2026-08-06]
Q2 net cash used in operating and investing activities was $25.7 million; the pace of future spending and year-end cash guidance require monitoring.

WatchKey bullets

TargetTau-1 Phase 2 primary completion

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=50%)

Target spread vs base: +53% / -47%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $9 (p=50%)Bear Target: $5 (p=25%)

Commentary

The available news set is thin. The stored AP Q2 snapshot reported adjusted loss of $0.32 per share versus a three-analyst estimate of $0.39, but current analyst revisions and a reliable post-release price reaction are unavailable. Recent Form 4 purchases by a 10% owner are disclosed activity, not evidence of trial outcomes. [#SEC-FORM4-2026-10-15] Social, options, short-interest, and employee metrics are unavailable; the zero fields above denote missing data, not neutral readings.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Bristol Myers Squibb decision on PRX019
Partnered Phase 3 trial execution

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
TargetTau-1 Phase 2 primary completion
Bristol Myers Squibb expects primary completion of its moponetug trial in early Alzheimer's disease in the first half of 2027. Completion is not itself a positive readout; delays or weak results remain material risks. [#SEC-8K-2026-08-06]
Prob 70.00% • Move 18.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Bristol Myers Squibb decision on PRX019
2026-12-31
Prothena said Bristol Myers Squibb's decision on whether to advance PRX019 is expected by year-end 2026; advancement could trigger a $55 million clinical milestone. The payment is contingent, not assured. [#SEC-8K-2026-08-06]
Prob 50% • Move 15% • Priced-in 25%

Long-term Catalysts

Months to a year

Partnered Phase 3 trial execution
2029-12-31
Roche's prasinezumab PARAISO trial and Novo Nordisk's coramitug CLEOPATTRA trial each have primary completion expected in 2029. Milestone and royalty potential is substantial but contingent on long-duration clinical success. [#SEC-8K-2026-08-06]
Prob 35% • Move 45% • Priced-in 15%

Risks

Clinical failure, delay, or a decision not to advance partner-controlled programs could eliminate anticipated milestones. [#SEC-8K-2026-08-06]
Q2 net cash used in operating and investing activities was $25.7 million; the pace of future spending and year-end cash guidance require monitoring. [#SEC-8K-2026-08-06]
The October chief development officer departure creates a leadership-transition question, although the filing says the executive will lead a partnered program at a strategic partner and does not identify an adverse program change. [#8-K-2026-10-02]

Peers

Symbol	Summary
TECX	Similar-sized biotechnology candidate; program and partnership economics are not established as comparable.
ASMB	Similar-sized biotechnology candidate; different programs make it a clinical-risk comparator, not a direct valuation peer.
ZURA	Similar-sized biotechnology candidate; useful only as a broad event-risk reference without indication-level comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

TECX

Similar-sized biotechnology candidate; program and partnership economics are not established as comparable.

ASMB

Similar-sized biotechnology candidate; different programs make it a clinical-risk comparator, not a direct valuation peer.

ZURA

Similar-sized biotechnology candidate; useful only as a broad event-risk reference without indication-level comparability.